Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement
The second in our series of skills webinars for the BIA Finance and Tax Community explored the key considerations for biotech companies expanding overseas, with insights and reflections from advisors and company leaders with firsthand international experience.
Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.
This 2026 update provides a critical reality check on the UK biotech sector, benchmarking the extraordinary resilience of female leaders against a plateauing representation and a shifting global tide of systemic challenges.
The BioIndustry Association (BIA) has recognised the achievements of Dr Ruth McKernan CBE, neuroscientist, entrepreneur, investor and former Chair of the BIA Board, with the inaugural Chiswell Lifetime Achievement Award.
Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.
Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.
The first in a new series of skills webinars for the BIA Finance and Tax Community explored some of the most significant milestones in a company’s growth journey, with insights and reflections from experts with firsthand experience.
This webinar spotlighted the latest capabilities from Our Future Health, the UK’s largest health research programme, now offering imputed and geographic data, dispensed medication records, and direct participant recruitment pathways.
In this analysis by Dr Martin Turner, Director of Policy and External Affairs, BIA, discover how the 2025 Budget could supercharge UK life sciences scale-ups with major investment incentives - while also highlighting potential risks from rising business rates.
Read our statement welcoming the Chancellor’s extended venture investment tax incentives and support for employee share options, as well as the prioritisation of tax and spending decisions in areas where the UK can lead and win.
London Life Sciences Week was a huge success last week, with significant increase in investors and life sciences execs coming together to connect and network. Combined with the news of two new significant fund raises from Sofinnova and Medicxi and progress towards completion of the British Growth Partnership Fund, it did feel that the sector found a lot to be hopeful about.
This blog explores the transformative BIA MAC Leadership Programme (LeaP) — a unique initiative empowering emerging bioprocessing professionals to accelerate their careers and strengthen leadership across the UK life sciences sector. With 76% of participants reporting career progression, LeaP is shaping the next generation of biotech leaders.
Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion.
New Q3 financing data reveals how these pressures are reshaping UK venture capital and exposing a fragile moment for the sector. The findings underscore the urgent need for sustained government action to unlock long-term growth capital and maintain the UK’s global competitiveness.
